心血管

订阅

MedSci主页 / 所有栏目 / 心血管

第22届HFSA：Sacubitril / Valsartan降低死亡率并改善心衰患者的预后

2018-09-23 MedSci MedSci原创

ValsartanSacubitril心衰
关注

根据美国心力衰竭学会（HFSA）第22届年会上发表的一项研究，脑啡肽酶抑制剂沙库必曲Sacubitril（沙库必曲）/ 血管紧张素Ⅱ受体拮抗剂Valsartan（缬沙坦）即LCZ696（Entresto），可以使心衰患者的射血分数（HFrEF）迅速恢复。

根据美国心力衰竭学会（HFSA）第22届年会上发表的一项研究，脑啡肽酶抑制剂沙库必曲Sacubitril（沙库必曲）/ 血管紧张素Ⅱ受体拮抗剂Valsartan（缬沙坦）即LCZ696（Entresto），可以使心衰患者的射血分数（HFrEF）迅速恢复。美国FDA于2015年7月7日批准诺华公司的Sacubitril / Valsartan片剂上市，用于射血分数降低的慢性心力衰竭（NYHA心功能Ⅱ~Ⅳ级）患者，以降低心力衰竭相关心血管死亡和住院风险。

俄亥俄州克利夫兰诊所的Nancy M. Albert博士说：“使用回顾性设计和行政索赔数据，真实世界的研究结果证明了sacubitril / valsartan在降低发病率方面的益处，同时，使用sacubitril / valsartan可降低医疗费用，改善患者健康相关生活质量的指标”。研究人员使用堪萨斯城心肌病问卷-总体概要（KCCQ-OS）来评估来自美国140个治疗中心的3,436名心衰患者。


原始出处：

http://www.firstwordpharma.com/node/1592725#axzz5RuSmLB5m

本文系梅斯医学（MedSci）原创编译整理，转载需授权！

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2007791, encodeId=62af200e791f6, content=<a href='/topic/show?id=1c0a15832ac' target=_blank style='color:#2F92EE;'>#Sacubitril#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15832, encryptionId=1c0a15832ac, topicName=Sacubitril)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Sat Apr 27 11:34:00 CST 2019, time=2019-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356934, encodeId=fb2713569340e, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Sep 25 08:34:00 CST 2018, time=2018-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373429, encodeId=fd4c13e3429f5, content=<a href='/topic/show?id=2fd051939ab' target=_blank style='color:#2F92EE;'>#心衰患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51939, encryptionId=2fd051939ab, topicName=心衰患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Tue Sep 25 08:34:00 CST 2018, time=2018-09-25, status=1, ipAttribution=)]
    2019-04-27 gaoxiaoe

    #Sacubitril#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2007791, encodeId=62af200e791f6, content=<a href='/topic/show?id=1c0a15832ac' target=_blank style='color:#2F92EE;'>#Sacubitril#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15832, encryptionId=1c0a15832ac, topicName=Sacubitril)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Sat Apr 27 11:34:00 CST 2019, time=2019-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356934, encodeId=fb2713569340e, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Sep 25 08:34:00 CST 2018, time=2018-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373429, encodeId=fd4c13e3429f5, content=<a href='/topic/show?id=2fd051939ab' target=_blank style='color:#2F92EE;'>#心衰患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51939, encryptionId=2fd051939ab, topicName=心衰患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Tue Sep 25 08:34:00 CST 2018, time=2018-09-25, status=1, ipAttribution=)]
    2018-09-25 zhaojie88

    #ART#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2007791, encodeId=62af200e791f6, content=<a href='/topic/show?id=1c0a15832ac' target=_blank style='color:#2F92EE;'>#Sacubitril#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15832, encryptionId=1c0a15832ac, topicName=Sacubitril)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Sat Apr 27 11:34:00 CST 2019, time=2019-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356934, encodeId=fb2713569340e, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Sep 25 08:34:00 CST 2018, time=2018-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373429, encodeId=fd4c13e3429f5, content=<a href='/topic/show?id=2fd051939ab' target=_blank style='color:#2F92EE;'>#心衰患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51939, encryptionId=2fd051939ab, topicName=心衰患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Tue Sep 25 08:34:00 CST 2018, time=2018-09-25, status=1, ipAttribution=)]
    2018-09-25 yuanming7

    #心衰患者#

    0